FDA Approved: BLOXIVERZ — Supplemental Application (Exela Pharma Sciences, LLC)

View source ↗

Summary

The FDA approved a supplemental application for BLOXIVERZ (neostigmine methylsulfate) submitted by Exela Pharma Sciences, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• BLOXIVERZ (Neostigmine methylsulfate)

Snippet

SUPPL AP for BLOXIVERZ (NEOSTIGMINE METHYLSULFATE)